Jean-Pierre Rosat

4FOx Ventures Partners (4FOx Ventures Partners) is a venture capital firm founded in 2015 by Jean-Pierre Rosat. The firm is headquartered in Lausanne, Switzerland.

ecoRobotix SA develops new machines to make agriculture more environmentally friendly and economically competitive. It designs, produces and commercialize machines for agriculture based on autonomous robotic technologies, featuring a lower general impact on the environment than current equipment. The company was founded by Steve Tanner, Aur?lien G. Demaurex and Gabriele Mondada in 2011 and is headquartered in Yverdon-les-Bains, Switzerland.

Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.

Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland.

Picodrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. The company was founded by M. Eric Lucien, Jean-Pierre Rosat, and Christian Schmidt on October 5, 2007 and is headquartered in Lausanne, Switzerland.

Diagnoplex SA develops molecular diagnostics for colon cancer. It lead product, Colox is a minimally-invasive blood test developed for the systematic screening and detection of early and advanced colorectal cancer. The company was founded in April 2005 by Stavros Therianos, Curzio Roberto Maria Rüegg, Jacques R. Essinger and Jean-Pierre Rosat and is headquartered in Lausanne, Switzerland.